Case Info
Gadolinium-based MRI contrast agents (GCBAs)
Gadolinium-based MRI contrast agents (GCBAs) have been used since 1998 to increase the visibility of organs and tissues during a magnetic resonance imaging (MRI) procedure. They are injected via intravenous (IV) infusion prior to the procedure and have been used in about one-in-three MRIs to improve imaging quality.
Harmful Effects
Although gadolinium-based contrast agents (GBCAs) were initially considered “safe,” the U.S. Food and Drug Administration (FDA) issued a significant safety warning in 2007. As part of this, the FDA mandated that labels for GBCAs, including those for products such as Magnevist and Omniscan, feature a black box warning. A black box warning is the FDA’s most serious safety notice, indicating that the medication carries a significant risk of severe or life-threatening adverse effects. In the case of Magnevist, Omniscan, and other gadolinium MRI agents, the warning specifically highlights the potential for these agents to increase the risk of nephrogenic systemic fibrosis (NSF). NSF is a rare but serious disorder that can affect various tissues in the body, including the skin, muscles, and internal organs. It primarily affects individuals with impaired kidney function, as those with compromised or decreased kidney function are at an elevated risk for developing NSF following exposure to GBCAs.
In 2014, a pivotal study revealed that gadolinium may accumulate in the brain and remain there for extended periods. This finding raised concerns about potential long-term side effects, particularly those impacting the central nervous system.
Lawsuits and Settlements
Bayer, GE Healthcare, and other manufacturers of gadolinium-based contrast agents (GBCAs) have faced over 1,000 lawsuits from individuals alleging serious injuries caused by these products. Among the plaintiffs was Gena Norris, the wife of well-known actor Chuck Norris, who filed a lawsuit in 2017 arguing that GBCAs led to severe health complications, including kidney damage.
One notable case involved GE Healthcare, which lost a trial in 2013 and was ordered to pay $5 million in damages to a man from Ohio who had suffered harm from the use of a GBCA.
Many lawsuits against GBCA manufactures were consolidated into the Gadolinium Contrast Dyes Products Liability Litigation. A significant number of these cases have been settled through both group and individual negotiations. As of November 2022, there have been no new developments in the litigation.